+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years - 65Years
FEMALE
ID07397325

Study of DA-020 and DA-020 with Hyperforin for Preventing Hair Loss in Women Undergoing Chemotherapy for Early Breast Cancer

Led by Applied Biology, Inc. · Updated on 2026-08-21

60

Participants Needed

2

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating DA-020 as a treatment to prevent hair loss caused by chemotherapy, a common and distressing side effect especially for women with breast cancer. This study aims to test whether DA-020, a topical formula containing an 1 agonist, can reduce scalp blood flow and thereby minimize chemotherapy-induced alopecia. The trial is sponsored by Applied Biology, Inc. and focuses on patients with early-stage breast cancer undergoing taxane andor anthracycline chemotherapy. Participants will be randomly assigned to one of three groups topical DA-020 solution, topical placebo solution, or a combination of DA-020 with Hyperforin 1.5%. Each active treatment involves applying 7 mL of the solution to the scalp. The study is designed as a randomized, quadruple-masked trial with parallel groups. The main treatment period lasts 12 weeks, with additional follow-up up to 24 weeks to assess hair regrowth. During the trial, participants will be monitored regularly for hair loss prevention using standardized criteria. Researchers will assess hair loss at baseline and throughout the 12-week treatment and evaluate hair regrowth up to 24 weeks after treatment start. Safety and adherence will be tracked along with any side effects. The total study duration spans from May 2026 to March 2027, including screening, treatment, and follow-up phases.

CONDITIONS

Brief Title

Clinical Study of DA-020 for the Treatment of Chemotherapy Induced Alopecia

Research Team

A

Andy Goren, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here